###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
PALB2 variants in hereditary and unselected Finnish Prostate cancer cases
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
PALB2 1592delT mutation is associated with increased breast cancer and suggestive prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants associate to increased PRCA risk and clinically describe patients with formerly found PALB2 1592delT mutation.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2</italic>
Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285) with complete clinical data were initially screened for variants in the coding region and splice sites of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n = 463).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2</italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
From our clinically defined sample set we identified total of six variants in PALB2. No novel variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers, including the previously described family carrying PALB2 1592delT, revealed a trend towards aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C (MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency among carriers with altered genotype.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
Though any of the detected PALB2 variants do not associate to PRCA in population level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility at individual level.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 69 72 <span type="species:ncbi:9606">men</span>
Prostate cancer (PRCA) is the most frequently diagnosed cancer among men in the Western world [1]. The incidence of PRCA has been increasing throughout the last decade, partly due to the earlier diagnosis provided by the prostate specific antigen (PSA) test, introduced in the 1990s. In Finland, the highest incidence of 115/100 000 was observed in 2005. In 2007 there were 4188 newly-diagnosed PRCA cases with the age-adjusted incidence rate of 85.9/100,000 [2]. Similar high increase and now decline have been observed in most Western industrialized countries [3].
###end p 10
###begin p 11
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
Extensive efforts have been made to reveal the genetics behind PRCA susceptibility [4]. Early linkage studies and more recent genome-wide association analyses have revealed multiple susceptibility loci for PRCA [5-7]. However, both causal variants and genes of the associated loci in are still not known and the identified PRCA risk variants only account for a fraction of the overall genetic variance for PRCA risk [8-10].
###end p 11
###begin p 12
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 410 416 410 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 780 786 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 856 862 856 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1006 1014 1006 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2 </italic>
###xml 1103 1105 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1385 1391 1385 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 1420 1422 1420 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1448 1453 1448 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1501 1508 1501 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2</italic>
###xml 1588 1590 1588 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1093 1101 <span type="species:ncbi:9606">patients</span>
DNA repair pathway genes have an undisputed role in cancer progression and inherited mutations in them have been strongly associated with different cancers. BRCA1 and BRCA2 are both tumor suppressor genes involved in DNA repair and mutations in these genes predominantly predispose carriers to breast and ovarian cancers [11]. Potential links to PRCA have been studied for both of these genes and mutations in BRCA2 lead to an increased risk for the disease in multiple studies [12,13]. In an Icelandic study, mutations in BRCA2 (999del5, Icelandic founder mutation) are associated with a poorly differentiated, advanced type of PRCA [14]. These results are also consistent with results from a recent study in the UK, where a significantly higher Gleason score was observed among BRCA2 mutation carriers than with non-carriers. These findings suggest that BRCA2 is a high-risk PRCA susceptibility gene and mutational analysis could be used as a prognostic marker for aggressive PRCA [15]. However, Finnish BRCA1/2 founder mutations do not associate with PRCA predisposition among Finnish PRCA patients [16]. This does not exclude the possibility of these genes to be involved in PRCA susceptibility but no studies have been published where the whole genes would have been sequenced in large data sets. Nevertheless an increased risk for PRCA in Finnish breast cancer families carrying BRCA2 mutations has been observed [17]. Moreover, mutations of CHEK2, a gene acting in the same DNA repair route as BRCA1/2, have been shown to have a significant role in PRCA susceptibility in Finland [18].
###end p 12
###begin p 13
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 881 887 881 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 913 919 913 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 597 604 <span type="species:ncbi:9606">patient</span>
###xml 823 831 <span type="species:ncbi:9606">patients</span>
###xml 969 977 <span type="species:ncbi:9606">patients</span>
PALB2 is a BRCA2 binding protein and the BRCA2-PALB2 interaction is essential for BRCA2-mediated DNA repair [19]. Recently it was shown that proper PALB2 function is necessary for the homologous recombination repair via interaction with BRCA1, revealing that PALB2 is actually a linker between BRCA1 and BRCA2 [20]. In the Finnish study by Erkko and colleagues a novel PALB2 founder mutation (c.1592delT) was identified among Finnish breast cancer families (OR 11.3, CI 1.8-57.8) increasing the risk to breast cancer 4-fold [21]. In the same study the c.1592delT mutation was observed also from a patient with familial PRCA (1/164) but none of 475 unselected cases were carriers of the mutation. No statistically significant association with PRCA and c.1592delT was detected and no other variants were screened for in PRCA patients. Here, to investigate the role of possible other PALB2 variants, we screened all PALB2 exons(exons 1-13) in a cohort of 938 Finnish PRCA patients including both familial and unselected cases.
###end p 13
###begin title 14
Material and methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 15
###begin p 16
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
A population-based cohort was collected from 1999 to 2005 from patients diagnosed with PRCA in the Pirkanmaa Hospital District that serves a population of a half a million inhabitants. The mean age at diagnosis for the 760 unselected patients was 62 (range 43-77), The median primary PSA and Gleason score were 8.9 and 6.4, respectively. The controls (n = 760) consisted of DNA samples from anonymous male blood donors obtained from the Finnish Red Cross.
###end p 16
###begin p 17
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
A detailed description of the collection of the PRCA families has been previously described elsewhere [22]. In this study, we analysed 178 families (youngest affected male from each family) with two or more affected first-degree relatives. The average number of affected family members was three. Familial cancer data was attained from the Finnish Cancer Registry and detailed clinical information, including Gleason score, WHO grade, PSA at the time of diagnosis, TNM stage and primary treatment from hospital records.
###end p 17
###begin p 18
###xml 189 197 <span type="species:ncbi:9606">patients</span>
To examine the association between the variants and the disease aggressiveness a subgroup of 380 with clinically aggressive disease was analyzed. Consequently clinically aggressive disease patients were selected according to Gleason score over seven and an age at diagnosis less than 61 years.
###end p 18
###begin title 19
Mutation analysis of PALB2
###end title 19
###begin p 20
###xml 69 75 69 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2</italic>
###xml 488 494 488 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
All familial samples had been previously screened for the 11 Finnish BRCA1 and seven BRCA2 founder mutations [16]. DNA samples from each family (n = 178), 285 unselected cases and 470 control samples were initially used for direct sequencing of the entire coding region and splice sites of PALB2. Unselected cases for screening the whole gene were early onset cases with Gleason score over seven. Additional analyses were carried out on four variants that showed a trend for association (PALB2 c.1592delT, 1674A>G, 2993G>A and 3300T>G). Unselected cases for additional analysis included 95 early onsets, aggressive cases and 368 non-aggressive cases with average age at diagnosis 67 years (range 63-77). Control samples in both primary and additional analysis were anonymous male blood donors from the Finnish Red Cross.
###end p 20
###begin p 21
###xml 291 297 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 562 568 562 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 832 840 <span type="species:ncbi:9606">patients</span>
Mutation detection was performed through resequencing using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit with the ABI 3130xl sequencer (Applied Biosystems). Primers and the naming of sequence variants were produced to correspond to the GenBank reference sequences for PALB2 (). Primer sequences are available on request. Variants were identified using Sequencher software 4.7 (Gene Codes Corporation, Ann Arbor, Mi). Loss of heterozygosity (LOH) analysis was carried out on two available tumor samples from the family with the segregating PALB2 1592delT. Selected sections of formalin fixed paraffin embedded tumors were obtained according to pathologist declaration. After tumor deparaffinization, DNA was extracted using a standard proteinase K protocol. Sequence from the tumor samples was compared to the patients' DNA sample from their peripheral blood.
###end p 21
###begin title 22
DNA damage response in PALB2 deficient cell line
###end title 22
###begin p 23
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 320 324 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
###xml 115 133 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Peripheral blood leucocytes from two cancerous individuals carrying PALB2 1592delT mutation were immortalized with Epstein-Barr virus (EBV) and sensitized to DNA crosslinking agent mitomycin C (MMC). Cells were treated with 0 nM, 1 nM, 5 nM, 10 nM and 50 nM MMC for 96 h and their viability was assayed by CellTiter-Blue(R) Cell Viability Assay (Promega Corporation, Madison, WI, USA).
###end p 23
###begin title 24
Statistical analyses
###end title 24
###begin p 25
###xml 336 342 336 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
To validate significance of variants, the odds ratios and 95% confidence intervals were calculated and association analyses were made using the Fisher's exact test. Analyses were done using SPSS 12.0 statistical software. Pairwise linkage disequilibrium between three most frequently detected variants (1674A>G, 2993G>A and 3300T>G) in PALB2 were analysed with Haploview 4.1. To define the haplotypes of cases familial and unselected cases were combined.
###end p 25
###begin title 26
Results and Discussion
###end title 26
###begin title 27
Mutation analysis
###end title 27
###begin p 28
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2</italic>
###xml 478 484 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1127 1128 1127 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 1139 1140 1139 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1629 1631 1629 1631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 2143 2145 2143 2145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 2186 2188 2186 2188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1253 1261 <span type="species:ncbi:9606">patients</span>
###xml 2133 2141 <span type="species:ncbi:9606">patients</span>
Prompted by the previous observation that the Finnish truncating founder mutation, PALB2 c.1592delT, was identified segregating in one family with four PRCA cases [21], we wanted to study the contribution of other possible PALB2 mutations. Probands from 178 Finnish HPC (hereditary prostate cancer) families and 285 unselected cases were screened for the entire coding region of PALB2. Total of six variants were detected in the coding regions and the exon-intron boundaries of PALB2 (Table 1). All the variants have been previously described and only the truncating mutation (c.1592delT) has been shown to have functional consequences on DNA damage response. Association of four detected variants (c.1592delT, 1674A>G, 2993G>A and 3300T>G) were assessed in more detail in a larger set of unselected cases and controls. The truncating c.1592delT mutation was detected in two sporadic cases in addition to the previously described family 310 and in one control sample [21]. Interestingly, family 310 has now been found to have also stomach and skin cancer, in addition to earlier described breast cancer, as indicated in Figure 1 and Table 2. Three of the detected variants, 1674A>G in exon 4, 2993G>A in exon 9 and 3300T>G in exon 12, co-existed in six patients out of 178 familial samples (OR 1.52 CI 95% 0.6-3.9), 20/748 unselected cases (OR 1.20 CI 95% 0.6-2.3) and in 17/760 of the controls. To assess question whether these three variants have a stronger joint effect that would strengthen the trend seen with singletons a haplotype analysis was performed. The strongest linkage was between 1674A>G and 2993G>A (D'= 0.975; r2 = 0.14, LOD 34.7) when 1886 case chromosomes and 1714 control chromosomes were analysed. Although these two variants appeared to have a frequency in PRCA cases that is higher than the Finnish population control frequency, their combined haplotype gave no improved results, i.e. none of the haplotype combinations showed significant association with the disease. Variant 2993G>A is now reported for the first time in the Finnish population since it did not come up in the study of Finnish breast cancer patients [21]. As reported by Rahman and colleagues [23] the 2993G>A variant is possibly damaging to protein function, based on SIFT (sorting intolerant from tolerant) analysis.
###end p 28
###begin p 29
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB </italic>
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Family 310 segregating the <italic>PALB </italic>mutation</bold>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 67 73 <span type="species:ncbi:9606">person</span>
###xml 213 219 <span type="species:ncbi:9606">person</span>
###xml 274 281 <span type="species:ncbi:9606">persons</span>
###xml 401 408 <span type="species:ncbi:9606">patient</span>
Family 310 segregating the PALB mutation. Minus-symbol signifies a person that has been screened for the PALB2 1592delT mutation, but found negative. Clinical information on this family is found in Table 2. Index person is marked with a black triangle, black square denotes persons with prostate cancer, grey circle indicates breast cancer cases and black square with white and grey corners signifies patient with prostate, stomach and skin cancers.
###end p 29
###begin p 30
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
Observed PALB2 variants among the Finnish familial and unselected prostate cancer cases.
###end p 30
###begin p 31
###xml 44 51 <span type="species:ncbi:9606">patient</span>
Clinical characteristics of family 310. The patient number refers to the number in the pedigree in Figure 1.
###end p 31
###begin p 32
IHC = immunohistochemistry, NA = not available
###end p 32
###begin p 33
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 389 395 389 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
We found that the 2993G>A variant exhibits a borderline significant odds ratios in a subgroup of 380 unselected cases with a Gleason score over seven and an age at diagnosis less than 61 years (20/380; OR 1.9; 95% CI 1.0-3.5). Edwards and colleagues [24] have presented similar age related observation with BRCA2 mutations in prostate cancer. They reported protein truncating mutations in BRCA2 to associate with PRCA diagnosed at or before age of 55. Our subgroup analysis also revealed that the variant 1674A>G has an OR of 1.4 (86/380; 95% CI 1.0-1.9) in a group of 368 patients with an average age at diagnosis of 67 years. However, the 1674A>G variant is commonly found in the Finnish population and well tolerated according to SIFT analysis, indicating no clear contribution to cancer formation. Similarly, the Val932 Met (2794G>A) change in exon 8 is well tolerated and has no effect on protein function [23].
###end p 33
###begin p 34
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2</italic>
###xml 525 531 525 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
In order to obtain information about loss of heterozygosity in the tumors from c.1592delT mutation positive patients, two available paraffin-embedded tumors were analysed. Repeated PCR-analysis did not reveal existence of LOH, which argues against the role as tumor suppressor gene. However the sample size is very small and therefore more tumor samples from PALB2-associated tumors needs to be characterized to be able to reliable assess PALB2 function in tumor formation. To date there is only one report indicating LOH in PALB2 related tumors. Unfortunately also this study lacks a statistical power to make an appropriate conclusion about the role of PALB2 in tumorigenesis [25].
###end p 34
###begin title 35
DNA damage response in PALB2 deficient cell line
###end title 35
###begin p 36
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
###xml 701 709 <span type="species:ncbi:9606">patients</span>
Previously, MMC sensitivity test to c.1592delT mutation has been done in a reporter cell line [21]. To test whether the previously described PALB2 c.1592delT mutation has functional consequences also in a heterozygous form, as present in all our patients, we predisposed two lymphoblast cell lines with c.1592delT and a wild type carrying control cell line to DNA cross linking agent MMC (Figure 2). c.1592delT mutation carriers were patients (15 and 24) from family 310 earlier described by Erkko et al. [21]. In both cell lines MMC-induced growth inhibition was observed suggesting PALB2 haploinsufficiency. It is also possible that dominant-negative effect is affecting in tumor formation in these patients.
###end p 36
###begin p 37
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mitomycin C growth inhibition in lymphoblastoid cell lines from the 310 family</bold>
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
Mitomycin C growth inhibition in lymphoblastoid cell lines from the 310 family. Black circle and square depicts cell lines derived from affected individuals with PALB2 1592delT mutation. Black triangle signs for control sample from healthy individual.
###end p 37
###begin p 38
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2 </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2</italic>
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 360 366 360 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 789 795 789 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1209 1211 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 710 718 <span type="species:ncbi:9606">patients</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
###xml 944 952 <span type="species:ncbi:9606">patients</span>
Geographical and ethnical differences in the PRCA susceptibility alleles have been previously reported in the CHEK2 gene that acts in the same pathway as PALB2, and therefore, variation in the PALB2 mutation spectrum in different populations would not be surprising. In the present study and in the study by Erkko et al. [21], the number of mutations found in PALB2 is relatively small among both Finnish breast and PRCA patients, with nine and six variants detected, respectively, compared to the British breast cancer family study by Rahman and colleagues [23] where a total of 50 variants and five frameshift mutations were reported. Recently, Tischkowitz and colleagues [26] reported a study of 95 US PRCA patients from Michigan, all diagnosed at < 55 years of age. Eleven variants in PALB2 were found, but none of them were truncating and no association with the disease was observed. When comparing our patients to those very early-onset patients studied by Tischkowitz and colleagues [26] there is a clear difference in the mean age of onset between the two datasets. On the other hand, no variants were found in the 14 Ashkenazi-Jewish and 21 French-Canadian PRCA cases with family history of cancer [27]. In Finland, the smaller number of variation found likely reflects the known genetic homogeneity and founder effect of the population [28].
###end p 38
###begin p 39
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PALB2 </italic>
Our findings indicate that no other deleterious PALB2 variants, except 1592delT mutation, contribute even marginally to PRCA risk in Finland. However, it remains possible that other genes from the BRCA1-PALB2-BRCA2 pathway have PRCA-predisposing alleles
###end p 39
###begin title 40
Competing interests
###end title 40
###begin p 41
The authors declare that they have no competing interests.
###end p 41
###begin title 42
Authors' contributions
###end title 42
###begin p 43
SP gathered the clinical data and aggregated the family structures of PRCA families and drafted the manuscript. TW and SS genotyped the cases and the controls. TW did the statistical calculations, contributed to study design and coordination and revised the manuscript. MP performed the MMC sensitivity test. MM and TT are the clinical contributors. JS participated in study design, interpreted the results and critically revised the manuscript. All the authors have read and approved the final manuscript.
###end p 43
###begin title 44
Acknowledgements
###end title 44
###begin p 45
###xml 17 25 <span type="species:ncbi:9606">patients</span>
We thank all the patients and their families for participation. We also thank Riitta Vaalavuo, RN for assistance and Linda Enroth for skilful technical assistance. This study was financially supported by the Competitive research funding of the Pirkanmaa Hospital District, the Reino Lahtikari Foundation, the Finnish Cancer Organizations, the Sigrid Juselius Foundation and the Academy of Finland (grants 118413 and 1126714). The Lindell foundation, the Paivikki and Sakari Sohlberg foundation and the Pirkanmaa Regional Fund of the Finnish Cultural Foundation have financially supported author SP.
###end p 45
###begin article-title 46
The prostate: an increasing medical problem
###end article-title 46
###begin article-title 47
Finnish Cancer Registry
###end article-title 47
###begin article-title 48
Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries
###end article-title 48
###begin article-title 49
The complex genetic epidemiology of prostate cancer
###end article-title 49
###begin article-title 50
A candidate prostate cancer susceptibility gene at chromosome 17p
###end article-title 50
###begin article-title 51
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1
###end article-title 51
###begin article-title 52
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk
###end article-title 52
###begin article-title 53
ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer
###end article-title 53
###begin article-title 54
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer
###end article-title 54
###begin article-title 55
Germ-line alterations in MSR1 gene and prostate cancer risk
###end article-title 55
###begin article-title 56
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
###end article-title 56
###begin article-title 57
###xml 44 52 <span type="species:ncbi:9606">patients</span>
BRCA2 mutation in Icelandic prostate cancer patients
###end article-title 57
###begin article-title 58
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian
###end article-title 58
###begin article-title 59
Prostate cancer progression and survival in BRCA2 mutation carriers
###end article-title 59
###begin article-title 60
A review of targeted screening for prostate cancer: introducing the IMPACT study
###end article-title 60
###begin article-title 61
BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland
###end article-title 61
###begin article-title 62
Risk of cancer in BRCA1 and BRCA2 mutation-positive and-negative breast cancer families (Finland)
###end article-title 62
###begin article-title 63
CHEK2 variants associate with hereditary prostate cancer
###end article-title 63
###begin article-title 64
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2
###end article-title 64
###begin article-title 65
PALB2 links BRCA1 and BRCA2 in the DNA-damage response
###end article-title 65
###begin article-title 66
A recurrent mutation in PALB2 in Finnish cancer families
###end article-title 66
###begin article-title 67
###xml 88 91 <span type="species:ncbi:9606">men</span>
Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families
###end article-title 67
###begin article-title 68
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
###end article-title 68
###begin article-title 69
###xml 15 18 <span type="species:ncbi:9606">men</span>
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
###end article-title 69
###begin article-title 70
Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families
###end article-title 70
###begin article-title 71
Analysis of the gene coding for the BRCA2-Interacting protein PALB2 in hereditary prostate cancer
###end article-title 71
###begin article-title 72
Analysis of PALB2/FANCN-associated breast cancer families
###end article-title 72
###begin article-title 73
###xml 33 38 <span type="species:ncbi:9606">human</span>
Disease gene mapping in isolated human populations: the example of Finland
###end article-title 73

